Welcome to our dedicated page for Evaxion AS SEC filings (Ticker: EVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evaxion A/S (EVAX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, primarily filed as Form 6-K current reports and other registration statements. As a foreign private issuer listed on the Nasdaq Capital Market, Evaxion files under Form 20-F and uses Form 6-K to furnish press releases and key corporate information to investors.
Evaxion’s recent 6-K filings frequently incorporate press releases that describe clinical and preclinical data from its AI-Immunology™ powered vaccine programs, including oncology candidates such as EVX-01 and EVX-04 and infectious disease programs like EVX-V1 and EVX-B2. These filings can give investors additional context on trial design, data readouts, and scientific presentations at major conferences.
Other 6-K reports document capital structure changes, such as amendments to the Articles of Association following share capital increases from investor warrant exercises. These filings outline new share issuances, nominal capital changes and related cash considerations, helping readers understand dilution, equity financing and the evolution of Evaxion’s capital base.
Evaxion also uses 6-Ks to furnish business updates and financial results, including quarterly performance, cash runway commentary, partnership income from out-licensed assets like EVX-B3, and information on capital market activities. In addition, the company’s registration statements on Forms F-1, F-3 and S-8 are referenced in 6-Ks through incorporation by reference language, indicating how new disclosures become part of existing prospectuses.
On Stock Titan, these filings are presented with AI-powered summaries that highlight the main points of each document, from scientific milestones to financing transactions. Users can quickly scan new 6-K submissions, identify filings related to clinical data, capital raises or governance changes, and then dive into the full text for deeper analysis. This page is a central resource for tracking EVAX’s regulatory reporting, capital markets activity and the formal record of its AI-Immunology™ platform and pipeline developments.
Evaxion A/S, a clinical-stage TechBio company developing AI-Immunology™ powered vaccines, has promoted Chief Scientific Officer Birgitte Rønø to a dual role as Chief Scientific and Chief Operating Officer. This change follows an internal management review aimed at aligning the organization to better execute its strategy and increase external visibility of its AI-Immunology™ platform with partners and investors.
The promotion recognizes Dr. Rønø’s long-standing contribution to Evaxion’s internal operations and scientific leadership. Following the change, the management team consists of CEO Helen Tayton-Martin, CSO and COO Birgitte Rønø, CFO Thomas Schmidt, and Chief AI Officer Andreas Mattsson. The filing also reiterates Evaxion’s focus on AI-driven vaccine candidates for cancer and infectious diseases.
Evaxion A/S director Jens Bitsch-Norhave filed an initial Form 3 reporting indirect ownership of 2,376 Ordinary Shares. The shares are held through Sprout Invest Aps, an entity owned 50% by Mr. Bitsch-Norhave and 50% by his spouse. The filing does not report any new buy or sell transactions.
Evaxion A/S reported the results of its Annual General Meeting held on April 16, 2026. Shareholders representing 104,894,401 ordinary shares, or 25,15 % of the share capital, were present or represented.
The audited annual report for 2025 and the carry-forward of the 2025 loss were approved. All incumbent directors standing for election were re-elected, and Jens Bitsch-Nørhave joined as a new board member. EY Godkendt Revisionspartnerselskab was re-appointed as auditor.
Shareholders approved an increase in the board’s authorization to issue warrants up to a nominal DKK 11,900,000, valid until April 15, 2029, and a new authorization to obtain loans through convertible loan notes up to a nominal DKK 73,500,000, valid until April 15, 2031, both without pre-emptive rights for existing shareholders. The Articles of Association were amended accordingly.
Evaxion A/S reports new phase 2 data for its personalized cancer vaccine EVX-01, showing that 86% of vaccine targets selected by its AI-Immunology™ platform triggered a tumor-specific immune response in advanced melanoma patients. The company also observed durable vaccine-specific immune responses lasting at least two years and a high rate of de novo tumor-specific T cells, indicating strong immune activation. The ongoing phase 2 trial combines EVX-01 with MSD’s KEYTRUDA® and has previously delivered a 75% Objective Response Rate, with three-year clinical data planned for the second half of 2026. The new data will be presented at the AACR Annual Meeting on April 22, 2026.
Evaxion A/S reports new phase 2 data for its personalized cancer vaccine EVX-01, showing that 86% of vaccine targets selected by its AI-Immunology™ platform triggered a tumor-specific immune response in advanced melanoma patients. The company also observed durable vaccine-specific immune responses lasting at least two years and a high rate of de novo tumor-specific T cells, indicating strong immune activation. The ongoing phase 2 trial combines EVX-01 with MSD’s KEYTRUDA® and has previously delivered a 75% Objective Response Rate, with three-year clinical data planned for the second half of 2026. The new data will be presented at the AACR Annual Meeting on April 22, 2026.
Evaxion A/S, a clinical-stage TechBio company, reports new data from its AI-Immunology™ platform showing it can design personalized cancer vaccines for glioblastoma, a deadly brain cancer with limited treatment options.
Working with Duke University School of Medicine, Evaxion identified endogenous retrovirus (ERV)-derived antigens and additional neoantigens in glioblastoma tumor samples. ERVs, which are present in tumors but absent in normal tissue, are highlighted as an attractive new antigen source. Bioinformatic and experimental data indicate ERV-derived antigens can trigger immune responses and may help overcome challenges linked to low mutational burden in glioblastoma. The data will be presented at the American Association for Cancer Research Annual Meeting in San Diego on April 22, 2026.
Evaxion A/S, a clinical-stage TechBio company, reports new data from its AI-Immunology™ platform showing it can design personalized cancer vaccines for glioblastoma, a deadly brain cancer with limited treatment options.
Working with Duke University School of Medicine, Evaxion identified endogenous retrovirus (ERV)-derived antigens and additional neoantigens in glioblastoma tumor samples. ERVs, which are present in tumors but absent in normal tissue, are highlighted as an attractive new antigen source. Bioinformatic and experimental data indicate ERV-derived antigens can trigger immune responses and may help overcome challenges linked to low mutational burden in glioblastoma. The data will be presented at the American Association for Cancer Research Annual Meeting in San Diego on April 22, 2026.
Evaxion A/S, a clinical-stage TechBio company developing AI-Immunology™-powered vaccines, reported the results of its Annual General Meeting held at its offices in Denmark. The 2025 Annual Report was approved and all proposals from the Board of Directors were passed.
Shareholders re-elected Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner and Roberto Prego Pineda to the Board of Directors, and elected Jens Bitsch Nørhave as a new Board member. The company noted that minutes from the meeting are available on its website and reiterated its focus on AI-driven vaccine candidates in oncology and infectious diseases.
Evaxion A/S CAIO Andreas Holm Mattsson filed an amended Form 3 to detail his ownership of ordinary shares and warrants. He holds 1,382,395 ordinary shares directly and 4,142,521 ordinary shares indirectly through Mattsson Holding af 2008 ApS, where he is described as a control person.
The filing also lists several series of warrants over ordinary shares. These include warrants over 55,147 shares with a 0.7400 exercise price expiring on December 21, 2026, and warrants over 645,700 shares at 0.0590 per share expiring on January 31, 2030. Additional warrant positions cover 35,000 shares at 2.2300, 6,250 shares at 0.7500, 25,000 shares at 0.4000, and 125,000 shares at 0.0700, each expiring on December 31, 2031. Footnotes explain that some warrants arise from a private placement that closed on December 21, 2023 and a public offering that closed on January 31, 2025, with certain awards vesting monthly over 36 months from their initial exercise dates.
Evaxion A/S reports that the one-year extension of its phase 2 trial of personalized cancer vaccine EVX-01 in advanced melanoma has been completed, with the last patient visit now finished. Three-year clinical efficacy data are expected to be presented in the second half of 2026.
Earlier phase 2 results showed an Objective Response Rate of 75%, with 12 of 16 patients responding and four achieving complete responses. At two-year follow-up, 92% of patients were still responding with no relapses, tumor reduction was seen in 15 of 16 patients, and 81% of targeted neoantigens triggered potent T-cell responses. EVX-01 was reported as well tolerated.
Evaxion A/S director Marianne Soegaard has filed an amended Form 3 detailing her ownership of ordinary shares and warrants. She reports direct holdings of 3,361,687 ordinary shares, plus additional ordinary shares held indirectly through Soegaard & Jansen ApS and family members. The filing also lists multiple warrant positions over Evaxion ordinary shares with exercise prices ranging from $0.0590 to $5.3800 per share and expiration dates extending to 2036-12-31.
Evaxion A/S director Wegner Lars Aage Staal has reported his equity holdings in the company in an amended Form 3. The filing shows direct ownership of 129,139 Ordinary Shares and multiple series of Warrants over additional Ordinary Shares with different exercise prices and expiration dates.
The holdings include Warrants over 46,100 Ordinary Shares at an exercise price of $0.0590 per share expiring on January 31, 2030, and Warrants over 479,604 Ordinary Shares at $0.1000 per share expiring on December 31, 2036. Other reported Warrants cover 21,396 Ordinary Shares at $5.3800 per share and 36,765 Ordinary Shares at $0.7400 per share, with various vesting schedules and expiration dates noted in the disclosure.